From the Chinese healthcare perspective, this study supports the use of sintilimab plus chemotherapy as a cost-effective treatment strategy for patients with EGFR-mutated NSCLC who have progressed on EGFR TKI treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.